Literature DB >> 2317074

Growth failure secondary to moyamoya syndrome.

C A MacKenzie1, R D Milner, U Bergvall, T Powell.   

Abstract

We describe a boy who presented at the age of 7 years with short stature due to hypopituitarism. Six months after starting appropriate hormone replacement treatment at the age of 8 he suffered his first generalised convulsion. Further neuroradiological investigation led to the diagnosis of moyamoya syndrome.

Entities:  

Mesh:

Year:  1990        PMID: 2317074      PMCID: PMC1792215          DOI: 10.1136/adc.65.2.232

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  6 in total

1.  Prevalence of severe growth hormone deficiency.

Authors:  G V Vimpani; A F Vimpani; G P Lidgard; E H Cameron; J W Farquhar
Journal:  Br Med J       Date:  1977-08-13

2.  Intracranial aneurysm associated with cerebrovascular moyamoya disease. Report of a case and review of 13 cases.

Authors:  M Kowada; F Momma; K Kikuchi
Journal:  Br J Radiol       Date:  1979-03       Impact factor: 3.039

3.  Occlusive disease of intracranial main arteries with collateral networks in children.

Authors:  H Halonen; V Halonen; M Donner; M Iivanainen; M Vuolio; J Mäkinen
Journal:  Neuropadiatrie       Date:  1973-04

4.  Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain.

Authors:  J Suzuki; A Takaku
Journal:  Arch Neurol       Date:  1969-03

5.  Moyamoya and Fanconi's anemia.

Authors:  N Cohen; M Berant; J Simon
Journal:  Pediatrics       Date:  1980-04       Impact factor: 7.124

6.  Acute hemiplegia and cortical blindness due to moya moya disease: report of a case in a child with Down's syndrome.

Authors:  G O Schrager; S J Cohen; M P Vigman
Journal:  Pediatrics       Date:  1977-07       Impact factor: 7.124

  6 in total
  1 in total

1.  Growth failure secondary to moyamoya syndrome.

Authors:  G Kurlemann; D G Palm
Journal:  Arch Dis Child       Date:  1990-09       Impact factor: 3.791

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.